- +1 551 333 1547
- +44 2070 979277
- live:skype_chat
Neurosyphilis Comprehensive Study by Type (Asymptomatic Neurosyphilis, Meningeal Neurosyphilis, Meningovascular Neurosyphilis, General Paresis, Tabes Dorsalis), Application (Hospital, Clinics, Others), Drugs (Antibiotic Penicillin, Ceftriaxone, Antibiotics Probenecid, Others), Diagnosis (Physical Exam, Spinal Tap, Blood Tests, Imagine Tests) Players and Region - Global Market Outlook to 2027
Neurosyphilis Market by XX Submarkets | Forecast Years 2022-2027
About Neurosyphilis
Neurosyphilis is the contamination of spinal wire and brain. It is most frequent in a person who have untreated syphilis for lengthy length of time. This is normally brought about due to microorganism known as Treponema pallidum. This is the microorganism which motives syphilis. After getting contaminated with syphilis for the first time, there are probabilities of neurosyphilis after 10-20 years later. The fundamental signs of neurosyphilis are blindness, atypical walk, confusion, depression, dementia, headache, irritability, incontinence, terrible concentration, numbness in the toes, feet, or legs, seizures, tremors, stiff neck, visible disturbances, and weakness. Neurosyphilis is a complication of syphilis that can manifest at any time post-exposure with syphilis. With the introduction of penicillin, it had reached a nadir till the 2000s when it noticed a resurgence, mainly in these with high-risk conduct which include the MSM and HIV population. It can be asymptomatic or it can also end result in vary of ailments which consist of meningeal, meningovascular, general paresis, and tabes dorsalis. | Attributes | Details |
|---|---|
| Study Period | 2020-2027 |
| Base Year | 2021 |
| Unit | Value (USD Million) |
Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Neurosyphilis market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Abbott (United States), Eli Lilly and Company (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), Bayer AG (Germany), GlaxoSmithKline plc. (United Kingdom), Sanofi (France), Abbvie (United States), Biogen (United States) and J&J (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Roche (Switzerland), Takeda (Japan), Amgen (United States), AstraZeneca (United Kingdom) and Bristol-Myers (United States).
Segmentation Overview
AMA Research has segmented the market of Global Neurosyphilis market by Type (Asymptomatic Neurosyphilis, Meningeal Neurosyphilis, Meningovascular Neurosyphilis, General Paresis and Tabes Dorsalis), Application (Hospital, Clinics and Others) and Region. On the basis of geography, the market of Neurosyphilis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drugs, the sub-segment i.e. Antibiotic Penicillin will boost the Neurosyphilis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Physical Exam will boost the Neurosyphilis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Neurosyphilis Market Dynamics:
| Attributes | Details |
|---|---|
| Growth Drivers |
|
| Restraints |
|
| Road Blocks / Challenges |
|
| Gaps & Opportunities |
|
Market Leaders and their expansionary development strategies
In 2022, Bristol Myers Squibb and Turning Point Therapeutics, Inc. introduced a definitive merger settlement below which Bristol Myers Squibb will accumulate Turning Point Therapeutics for USD 76.00 per share. The transaction used to be unanimously authorized through each the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is expected to shut for the duration of the 0.33 quarter of 2022.In 2021, Abbott Launches Panbio™ COVID-19 Antigen Self-Test in India; Strengthens Rapid Diagnostics Portfolio to Support Testing Needs at Home, Work and at Clinics. Abbott has introduced the launch of Panbio™ COVID-19 Antigen Self-Test for the detection of the SARS-CoV-2 virus in adults and youngsters with or besides symptoms.
Key Target Audience
Neurosyphilis diagnostic and treatment supplies companies, Neurosyphilis diagnostic and treatment supplies providers, Medical research laboratories, Research and Development (R&D) Companies and OthersAbout Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global. Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.
Report Objectives / Segmentation Covered
By Type
- Asymptomatic Neurosyphilis
- Meningeal Neurosyphilis
- Meningovascular Neurosyphilis
- General Paresis
- Tabes Dorsalis
By Application
- Hospital
- Clinics
- Others
By Drugs
- Antibiotic Penicillin
- Ceftriaxone
- Antibiotics Probenecid
- Others
By Diagnosis
- Physical Exam
- Spinal Tap
- Blood Tests
- Imagine Tests
By Regions
- South America
- Brazil
- Argentina
- Rest of South America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Taiwan
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- Italy
- United Kingdom
- Netherlands
- Rest of Europe
- MEA
- Middle East
- Africa
- North America
- United States
- Canada
- Mexico
- 1. Market Overview
- 1.1. Introduction
- 1.2. Scope/Objective of the Study
- 1.2.1. Research Objective
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Growing Awareness Regarding Neurosyphilis
- 3.2.2. Increasing Demand from Emerging Markets
- 3.2.3. Government Support to Improve Public Healthcare
- 3.2.4. Changing Healthcare Practices
- 3.3. Market Challenges
- 3.3.1. Limited Growth of Neurosyphilis Market
- 3.3.2. Lack of Knowledge of Disease, Traditional Healthcare Practices
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 5. Global Neurosyphilis, by Type, Application, Drugs, Diagnosis and Region (value) (2016-2021)
- 5.1. Introduction
- 6. Neurosyphilis: Manufacturers/Players Analysis
- 6.1. Company Profile
- 6.1.1. Abbott (United States)
- 6.1.1.1. Business Overview
- 6.1.1.2. Products/Services Offerings
- 6.1.1.3. Financial Analysis
- 6.1.1.4. SWOT Analysis
- 6.1.2. Eli Lilly and Company (United States)
- 6.1.2.1. Business Overview
- 6.1.2.2. Products/Services Offerings
- 6.1.2.3. Financial Analysis
- 6.1.2.4. SWOT Analysis
- 6.1.3. Novartis AG (Switzerland)
- 6.1.3.1. Business Overview
- 6.1.3.2. Products/Services Offerings
- 6.1.3.3. Financial Analysis
- 6.1.3.4. SWOT Analysis
- 6.1.4. Pfizer Inc. (United States)
- 6.1.4.1. Business Overview
- 6.1.4.2. Products/Services Offerings
- 6.1.4.3. Financial Analysis
- 6.1.4.4. SWOT Analysis
- 6.1.5. Bayer AG (Germany)
- 6.1.5.1. Business Overview
- 6.1.5.2. Products/Services Offerings
- 6.1.5.3. Financial Analysis
- 6.1.5.4. SWOT Analysis
- 6.1.6. GlaxoSmithKline plc. (United Kingdom)
- 6.1.6.1. Business Overview
- 6.1.6.2. Products/Services Offerings
- 6.1.6.3. Financial Analysis
- 6.1.6.4. SWOT Analysis
- 6.1.7. Sanofi (France)
- 6.1.7.1. Business Overview
- 6.1.7.2. Products/Services Offerings
- 6.1.7.3. Financial Analysis
- 6.1.7.4. SWOT Analysis
- 6.1.8. Abbvie (United States)
- 6.1.8.1. Business Overview
- 6.1.8.2. Products/Services Offerings
- 6.1.8.3. Financial Analysis
- 6.1.8.4. SWOT Analysis
- 6.1.9. Biogen (United States)
- 6.1.9.1. Business Overview
- 6.1.9.2. Products/Services Offerings
- 6.1.9.3. Financial Analysis
- 6.1.9.4. SWOT Analysis
- 6.1.10. J&J (United States)
- 6.1.10.1. Business Overview
- 6.1.10.2. Products/Services Offerings
- 6.1.10.3. Financial Analysis
- 6.1.10.4. SWOT Analysis
- 6.1.1. Abbott (United States)
- 6.1. Company Profile
- 7. Global Neurosyphilis Sale, by Type, Application, Drugs, Diagnosis and Region (value) (2022-2027)
- 7.1. Introduction
- 8. Appendix
- 8.1. Acronyms
- 9. Methodology and Data Source
- 9.1. Methodology/Research Approach
- 9.1.1. Research Programs/Design
- 9.1.2. Market Size Estimation
- 9.1.3. Market Breakdown and Data Triangulation
- 9.2. Data Source
- 9.2.1. Secondary Sources
- 9.2.2. Primary Sources
- 9.3. Disclaimer
- 9.1. Methodology/Research Approach
List of Tables
- Table 1. Company Basic Information, Sales Area and Its Competitors
- Table 2. Company Basic Information, Sales Area and Its Competitors
- Table 3. Company Basic Information, Sales Area and Its Competitors
- Table 4. Company Basic Information, Sales Area and Its Competitors
- Table 5. Company Basic Information, Sales Area and Its Competitors
- Table 6. Company Basic Information, Sales Area and Its Competitors
- Table 7. Company Basic Information, Sales Area and Its Competitors
- Table 8. Company Basic Information, Sales Area and Its Competitors
- Table 9. Company Basic Information, Sales Area and Its Competitors
- Table 10. Company Basic Information, Sales Area and Its Competitors
- Table 11. Research Programs/Design for This Report
- Table 12. Key Data Information from Secondary Sources
- Table 13. Key Data Information from Primary Sources
List of Figures
- Figure 1. Porters Five Forces
- Figure 2. Supply/Value Chain
- Figure 3. PESTEL analysis
- Figure 4. Abbott (United States) Revenue, Net Income and Gross profit
- Figure 5. Abbott (United States) Revenue: by Geography 2021
- Figure 6. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
- Figure 7. Eli Lilly and Company (United States) Revenue: by Geography 2021
- Figure 8. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
- Figure 9. Novartis AG (Switzerland) Revenue: by Geography 2021
- Figure 10. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
- Figure 11. Pfizer Inc. (United States) Revenue: by Geography 2021
- Figure 12. Bayer AG (Germany) Revenue, Net Income and Gross profit
- Figure 13. Bayer AG (Germany) Revenue: by Geography 2021
- Figure 14. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
- Figure 15. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2021
- Figure 16. Sanofi (France) Revenue, Net Income and Gross profit
- Figure 17. Sanofi (France) Revenue: by Geography 2021
- Figure 18. Abbvie (United States) Revenue, Net Income and Gross profit
- Figure 19. Abbvie (United States) Revenue: by Geography 2021
- Figure 20. Biogen (United States) Revenue, Net Income and Gross profit
- Figure 21. Biogen (United States) Revenue: by Geography 2021
- Figure 22. J&J (United States) Revenue, Net Income and Gross profit
- Figure 23. J&J (United States) Revenue: by Geography 2021
List of companies from research coverage that are profiled in the study
- Abbott (United States)
- Eli Lilly and Company (United States)
- Novartis AG (Switzerland)
- Pfizer Inc. (United States)
- Bayer AG (Germany)
- GlaxoSmithKline plc. (United Kingdom)
- Sanofi (France)
- Abbvie (United States)
- Biogen (United States)
- J&J (United States)
Additional players considered in the study are as follows:
Roche (Switzerland)
,
Takeda (Japan)
,
Amgen (United States)
,
AstraZeneca (United Kingdom)
,
Bristol-Myers (United States)
Select User Access Type
Key Highlights of Report
Aug 2022
228 Pages
65 Tables
Base Year: 2021
Coverage: 15+ Companies; 18 Countries
Request Sample Pages
Budget constraints? Get in touch with us for special pricing
Check Discount Now
Talk to Our Experts
Want to Customize Study?
"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."
Frequently Asked Questions (FAQ):
The standard version of the report profiles players such as Abbott (United States), Eli Lilly and Company (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), Bayer AG (Germany), GlaxoSmithKline plc. (United Kingdom), Sanofi (France), Abbvie (United States), Biogen (United States) and J&J (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Neurosyphilis Market during projected period 2021-2027.
The Neurosyphilis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.